Cheap antioxidant could replace costly drugs for Post-Transplant blood disorder
NCT ID NCT07279610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether N-acetylcysteine (NAC), a common antioxidant, can treat a severe blood vessel condition called TA-TMA that can happen after a stem cell transplant. Current treatments are either ineffective or very expensive. The trial will enroll 44 adults diagnosed with TA-TMA and measure if NAC improves blood counts and organ function. If successful, NAC could offer a safe, affordable option for this life-threatening complication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Real-World data unlock clues to a deadly Post-Transplant complication?
- Engineered immune cells take on tough autoimmune diseases
- New drug aimed at saving lives after stem cell transplants
- New drug shows promise for rare post-transplant complication in kids
- New hope for stem cell transplant patients with dangerous blood clotting disorder